OPKO Health OPK-88006 Phase 1/2 Clinical Trial Registration
Summary
ClinicalTrials.gov registered a Phase 1/2 clinical trial (NCT07512427) sponsored by OPKO Health evaluating OPK-88006. The study registration provides standard protocol details including eligibility criteria, study design, and investigator information. ClinicalTrials.gov is maintained by the National Library of Medicine under NIH.
What changed
OPKO Health registered a new clinical trial (NCT07512427) on ClinicalTrials.gov for its investigational drug OPK-88006, designated as a Phase 1/2 study. The registration includes standard required elements such as study objectives, participant eligibility criteria, anticipated enrollment numbers, and participating investigator sites. This registration satisfies FDAAA 801 requirements for clinical trial registration.
Pharmaceutical sponsors conducting clinical trials must ensure Continuous US registry updates within 30 days of any protocol changes. Investigators should verify their site information is accurate and accessible. This registration establishes a public record of the trial for prospective participants and healthcare professionals.
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.